Evidence map›Paper›PMID 39663706›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2025

Conjugation Chemistry Markedly Impacts Toxicity and Biodistribution of Targeted Nanoparticles, Mediated by Complement Activation.

Michael H Zaleski, Liam S Chase, Elizabeth D Hood, Zhicheng Wang, Jia Nong, Carolann L Espy, Marco E Zamora, Jichuan Wu, Lianne J Morrell, Vladimir R Muzykantov and 2 more

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. DNA-directed assembly of multivalent lipid nanoparticles for targeted T cell gene delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Antibody-conjugated polymer nanoparticles for brain cancer.Drug delivery and translational research · 2025
    Review
  17. Review
  18. Article
  19. Article
  20. Rational design of lipid nanoparticles for enabling gene therapies.Molecular therapy. Methods & clinical development · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michael H ZaleskiDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.ORCID 0000-0002-8419-1718
Liam S ChaseDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.ORCID 0009-0005-9661-0720
Elizabeth D HoodDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.ORCID 0000-0002-6829-8339
Zhicheng WangDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.
Jia NongDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.ORCID 0000-0002-9210-7707
Carolann L EspyDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.
Marco E ZamoraDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.
Jichuan WuDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.
Lianne J MorrellDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.
Vladimir R MuzykantovDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.
Jacob W MyersonDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.
Jacob S BrennerDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, University of Pennsylvania, 421 Curie Blvd., 354 BRB II/III, Philadelphia, PA, 19104, USA.ORCID 0000-0001-8437-0161

Funding

PREDOCTORAL TRAINING PROGRAM IN PHARMACOLOGYT32GM008076 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI BLENDY, JULIE A · 1985 to 2023
$10.8M
Vascular Targeting of Nanocarriers for RNAR01HL155106 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R, WEISSMAN, DREW · 2021 to 2024
$3.1M
Dual drug delivery to lung/blood interface in respiratory infections.R01HL157189 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2021 to 2024
$2.9M
mRNA-LNPs for ARDSR01HL164594 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Jacob Brenner, Hamideh Parhiz · 2023 to 2026
$2.7M
Controlling complement to unleash nanomedicine for acute critical illnessesR01HL160694 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BRENNER, JACOB, MUZYKANTOV, VLADIMIR R · 2022 to 2025
$2.7M
Nanomedicine for ARDS: A new paradigm to target drugs to multiple cell types within alveolar capillariesR01HL153510 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BRENNER, JACOB · 2020 to 2024
$2.0M
Next-generation nanomedicine for acute ischemic strokeR41NS130812 · NINDS · NANOMUSE, LLC · PI BRENNER, JACOB · 2023 to 2025
$652k
RBC-mediated mopping of cytokines for the treatment of pneumoniaR21AI166778 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BRENNER, JACOB · 2021 to 2022
$447k
Commonwealth Universal Research Enhancement (CARES) ProgramFoundation for the National Institutes of Health 1R01HL164594Foundation for the National Institutes of Health 5R01HL153510Foundation for the National Institutes of Health 5R01HL155106Foundation for the National Institutes of Health 5R01HL157189Foundation for the National Institutes of Health 5R01HL160694Foundation for the National Institutes of Health 5R21AI166778Foundation for the National Institutes of Health T32GM008076NHLBI NIH HHS R01 HL153510NHLBI NIH HHS R01 HL155106NHLBI NIH HHS R01 HL157189NHLBI NIH HHS R01 HL160694NHLBI NIH HHS R01 HL164594NIAID NIH HHS R21 AI166778NIGMS NIH HHS T32 GM008076NINDS NIH HHS R41 NS130812Pennsylvania Department of Health
6 · The paper itself

Abstract

Conjugation chemistries are a major enabling technology for the development of drug delivery systems, from antibody-drug conjugates to antibody-targeted lipid nanoparticles inspired by the success of the COVID-19 vaccine. However, here it is shown that for antibody-targeted nanoparticles, the most popular conjugation chemistries directly participate in the activation of the complement cascade of plasma proteins. Their activation of complement leads to large changes in the biodistribution of nanoparticles (up to 140-fold increased uptake into phagocytes of the lungs) and multiple toxicities, including a 50% drop in platelet count. It is founded that the mechanism of complement activation varies dramatically between different conjugation chemistries. Dibenzocyclooctyne, a commonly used click-chemistry, caused aggregation of conjugated antibodies, but only on the surface of nanoparticles (not in bulk solution). By contrast, thiol-maleimide chemistry do not activate complement via its effects on antibodies, but rather because free maleimide bonded to albumin in plasma, and clustered albumin is then attacked by complement. Using these mechanistic insights, solutions are engineered that reduced the activation of complement for each class of conjugation chemistry. These results highlight that while conjugation chemistry is essential for the future of nanomedicine, it is not innocuous and must be designed with opsonins like complement in mind.

Indexed as

Complement ActivationNanoparticlesAnimalsClick ChemistryHumansImmunoconjugatesMaleimidesMiceTissue DistributionImmunoconjugatesmaleimideMaleimidescomplement systemconjugation chemistrydrug deliverynanomedicinetargeted nanoparticles

Identifiers

PMID39663706
PMCPMC11795710

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.